Abstract 4297
Background
Anxiety and distress may be experienced by cancer patients diagnosed with melanoma throughout their diagnosis and treatment. Beaumont Hospital, Dublin is a designated cancer centre and a proposal to develop an onsite melanoma patient support group (MPSG) in collaboration with the Skin Oncology CNSp, and the Cancer Nurse, Daffodil Centre, Beaumont Hospital was agreed. Aims/Objectives: To assess the interest in attending a professionally facilitated MPSG. To ascertain what type of group would benefit most. To ascertain the themes required to meet the needs of the group. To offer a supportive, safe environment for meeting and sharing experiences. To create an awareness of the support required by patients diagnosed with melanoma.
Methods
Initial planning meeting between the Skin Oncology CNS and the Cancer Nurse, resulted in an agreement to develop a MPSG. A target population was identified and the practicalities and commitment involved in co-facilitating a support group were identified. Group governance was developed. An expression of interest letter and a questionnaire was sent to the target population, specific themes were incorporated to assist development of the support group and manage its format and content.
Results
Patient responses identified a format for the support group incorporating educational and emotional support. Group rules were established and adhered to, with regular evaluation and discussion taking place allowing change to be incorporated as required. Six meetings took place in 2018/2019.
Conclusions
Future plans include: Maintain stability of the group. Continue meeting every two months. Attract new members. Review of group by questionnaire in relation to specific patient interests.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract